Arca
Skip to content
Tools
Tools

CNR2: Cannabinoid receptor 2

Heterotrimeric G protein-coupled receptor for endocannabinoid 2-arachidonoylglycerol mediating inhibition of adenylate cyclase.

  • Drugs that act on it: 8
  • Approved: 0
  • In phases 1 to 3: 8
  • Sponsors: 5

Who is on it, and how far along

Every drug ChEMBL records acting on CNR2, by the furthest stage it has reached for any use, coloured by modality.

How to read this

Each mark is one drug. Columns run from approved to phase 1; hover or tap a mark for its sponsor, modality and open trials, and click it to open the drug.

  • Small molecule 8

Approved0

    Phase 30

      Phase 27

      • GW842166X
      • LY2828360
      • Nonabine
      • Olorinab
      • PRS-211375
      • S-777469
      • Tedalinab

      Phase 11

      • SAD448

      Sponsors

      Drugs on this target per company: the US application holder, else the industry sponsor leading the most of its trials.

      The landscape

      Every drug acting on it, furthest along first. The sponsor is the US application holder where there is one, else the industry lead sponsor of most of its registered trials. All act as: Cannabinoid CB2 receptor agonist.
      GW842166XPhase 2GSKSmall moleculeAgonist0
      LY2828360Phase 2Eli LillySmall moleculeAgonist0
      NonabinePhase 2—Small moleculeAgonist0
      OlorinabPhase 2Arena PharmaceuticalsSmall moleculeAgonist0
      PRS-211375Phase 2—Small moleculeAgonist0
      S-777469Phase 2ShionogiSmall moleculeAgonist0
      TedalinabPhase 2—Small moleculeAgonist0
      SAD448Phase 1Novartis PharmaceuticalsSmall moleculeAgonist0

      Diseases most associated with it

      Open Targets association score, 0 to 1; all associations
      • Neurodegenerative disease0.21
      • Splenomegaly0.17
      • Neoplasm0.11
      • Pain0.10
      • Atopic eczema0.10
      • Alopecia universalis congenita0.10
      • Alzheimer disease0.10
      • Alopecia - intellectual disability syndrome0.10
      • Hypotrichosis simplex0.10
      • Crohn disease0.10
      • Breast carcinoma0.10

      Drugs, mechanisms, furthest stage (max phase) and modality (molecule type) are from ChEMBL CHEMBL253, ChEMBL 37, fetched 2026-11-18 (CC BY-SA 3.0). Sponsors are the US application holder (Drugs@FDA) for approved drugs with a US page, else the industry lead sponsor of the most of the drug's ClinicalTrials.gov trials. Open trials are recruiting or ongoing studies naming the drug as an intervention on ClinicalTrials.gov, checked daily; this page as of 2026-11-21. Gene name, function (UniProt P34972, CC BY 4.0) and disease associations are from Open Targets (CC0). ChEMBL and Open Targets

      Esc

      Type a name: a tool, a company, a drug or brand, a condition, a gene or a state. Identifiers like K231234, NCT05012345 or NDA 215866 open their record.

      Logos are each company's own site icon, matched by name through Wikidata, or logos provided by Logo.dev.Company names and logos identify the companies in public FDA and registry records and do not imply endorsement.